Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Cash from Financing Activities (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Cash from Financing Activities for 7 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 45.24% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $478.0 million through Dec 2025, up 6079.54% year-over-year, with the annual reading at $478.0 million for FY2025, 6079.54% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $1.9 million at Beam Therapeutics, up from $1.7 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $473.4 million in Q1 2025, with the low at $133000.0 in Q2 2024.
  • Average Cash from Financing Activities over 5 years is $81.5 million, with a median of $27.2 million recorded in 2022.
  • The sharpest move saw Cash from Financing Activities surged 341268.09% in 2021, then plummeted 99.88% in 2024.
  • Over 5 years, Cash from Financing Activities stood at $21.5 million in 2021, then soared by 48.6% to $32.0 million in 2022, then increased by 5.31% to $33.7 million in 2023, then crashed by 89.78% to $3.4 million in 2024, then tumbled by 45.24% to $1.9 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $1.9 million, $1.7 million, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.